Verdict: Side-by-side breakdown using the Bull Rankings model. HRMY scored 88.5, KRYS scored 70.7 — HRMY leads.
Compare another set
HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology · Quality-Growth
88.5
$40.28 · $2.3B
fundamentals as of
Score gap
17.8
HRMY leads
KRYS
Krystal Biotech, Inc.
Biotechnology · Quality-Growth
70.7
$331.61 · $9.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestHRMY13.0x
Fastest growthHRMY+24.3%
Strongest balance sheetKRYS0.01
Highest qualityHRMY79 / 100
Largest discount to fair valueHRMY-71%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HRMY
stronger →← stronger
KRYS
79
Qualityreturns · margins · balance sheet
70
95
Growthrevenue & earnings expansion
91
92
Valuevaluation vs sector peers
55
HRMY is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
HRMY
KRYS
$355mC
FCF
$258mC
+24.3%A-
Rev
+22.6%A-
0.16B+
D/E
0.01A
13.0xA
P/E
41.6xC
0.38A
PEG
2.10C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HRMY
KRYS
71% below
Price vs fair valuelower is cheaper
77% above
~-15%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~28%/yr
+168%
1-yr DCF upside
-55%
+249%
5-yr DCF upside
-43%
+413%
10-yr DCF upside
-22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HRMY
Why this score
Durable high returns
KRYS
Why this score
Diluting shareholders
The companies
HRMYHarmony Biosciences Holdings, Inc.
Biotechnology · $40.28 · beta 1.01
Why now
Biotechnology · market cap $2.3b. 7% off the 52-week high of $43.49. Revenue growing +24%, comfortably above the S&P median. PEG 0.38 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $47.64 (implying +18% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
KRYSKrystal Biotech, Inc.
Biotechnology · $331.61 · beta 0.50
Why now
Biotechnology · market cap $9.8b. 13% off the 52-week high of $382.54. Revenue growing +23%, comfortably above the S&P median. 9 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $392.11 (implying +18% upside).
Moat
Net margin 55% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 107% of net income — earnings translate cleanly into cash.
Risk
Trailing P/E 42x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 22.3x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HRMY and KRYS diverge
On the headline score the gap is 17.8 points in favor of HRMY. The widest single difference is Value, where HRMY leads by 36.9 points.
ValueHRMY 92.2 · KRYS 55.3HRMY +36.9
QualityHRMY 79.5 · KRYS 70.2HRMY +9.3
GrowthHRMY 94.5 · KRYS 91.1HRMY +3.4
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is HRMY or KRYS the better stock?
HRMY scores higher: HRMY 88.5, KRYS 70.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do HRMY and KRYS differ most?
The widest gap is value, where HRMY leads by 37 points on the 0–100 pillar scale. HRMY leads all three pillars, so the gap is broad rather than a single-measure difference.
How are HRMY and KRYS scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.